Orforglipron Dosage Guide
55/100 confidenceComplete guide to Orforglipron dosing protocols, administration methods, and safety considerations for research purposes.
Dosage Overview
Dose per Injection
12 mg – 45 mg
Frequency
Once per day
Route
oral
Detailed Dosage Information
Phase 2 trial doses
12 mg, 24 mg, 36 mg, and 45 mg daily.
The 36 mg and 45 mg doses showed greatest efficacy.
Phase 3 trials are evaluating doses of 12-60 mg daily.
No fasting requirement — can be taken with or without food at any time of day.
Final approved dosing not yet established.
Administration Method
Oral tablet, once daily. No fasting restrictions required (a major advantage over oral semaglutide). Phase 3 trials ongoing. Expected FDA decision in 2026. Not yet commercially available.
Research Backing
Phase 2 trial (NEJM, Frias et al. 2023): up to 14.7% weight loss at 36 weeks (45 mg). Phase 3 ATTAIN program ongoing. Eli Lilly pipeline. Analysts project $16B annual sales by 2031.
Side Effects to Monitor
Phase 2 data: nausea (up to 35%), vomiting (up to 19%), diarrhea (up to 18%), constipation, decreased appetite. GI side effects were dose-dependent and generally transient, decreasing with continued use. Discontinuation rates due to GI events were 6-12%.
Safety Considerations & Risks
Pre-approval medication — full safety profile not yet established. Thyroid C-cell tumor risk not yet fully assessed in humans (positive signal in rodent studies expected). Hepatic effects under evaluation. No long-term safety data beyond 36 weeks. Risk of drug-drug interactions with oral medications (GLP-1 effects on gastric emptying may alter absorption of other drugs).